Renal · Year 2 · from Renal

Case 2: Hyperkalemia in Diabetic Kidney Disease

Patient Presentation

A 62-year-old male with type 2 diabetes and stage 4 CKD (eGFR 22 mL/min) presents to the emergency department after his cardiologist noted "tall T waves" on a routine ECG. He reports no symptoms.

History of Present Illness

  • Routine cardiology follow-up for stable coronary artery disease
  • ECG changes prompted immediate ED referral
  • No chest pain, palpitations, or weakness
  • Medications: lisinopril 20 mg, metoprolol 50 mg, spironolactone 25 mg, empagliflozin 10 mg
  • Recently started on ibuprofen 600 mg TID for knee osteoarthritis

Physical Examination

  • Blood pressure: 142/88 mmHg
  • Heart rate: 58 bpm, regular
  • No peripheral edema
  • Normal strength throughout
  • Alert and oriented

Workup

Laboratory Studies:

  • Serum potassium: 6.8 mEq/L (severely elevated)
  • Creatinine: 2.8 mg/dL (baseline 2.4)
  • BUN: 48 mg/dL
  • Bicarbonate: 18 mEq/L (low - metabolic acidosis)
  • Glucose: 168 mg/dL

ECG:

  • Peaked, narrow T waves
  • PR interval 240 ms (prolonged)
  • QRS 110 ms (borderline widened)
  • No P wave loss or sine wave pattern

Diagnosis

Severe Hyperkalemia due to Type 4 RTA and Multiple Contributing Medications

Discussion

This case demonstrates multiple mechanisms of hyperkalemia:

  • Type 4 RTA (Hyporeninemic Hypoaldosteronism): Common in diabetic nephropathy. The lecture explains that hyperkalemia inhibits renal ammoniagenesis, reducing net acid excretion and causing the mild metabolic acidosis typical of type 4 RTA.
  • Medication Contributions: Multiple drugs that raise potassium - lisinopril (ACE inhibitor reduces aldosterone), spironolactone (blocks mineralocorticoid receptor), metoprolol (beta-blocker impairs cellular potassium uptake), ibuprofen (NSAID reduces prostaglandin-mediated renin release and directly affects potassium secretion).
  • ECG Changes: The lecture describes the progression of ECG changes - peaked T waves appear first (5.5-6.5 mEq/L), followed by PR prolongation and QRS widening (6.5-7.5 mEq/L).
  • Pseudohyperkalemia Excluded: The patient has no hemolysis, thrombocytosis, or leukocytosis, and ECG changes confirm true hyperkalemia.

Treatment

Immediate Management:

  • Calcium gluconate 10 mL of 10% IV over 2-3 minutes (membrane stabilization)
  • Regular insulin 10 units IV with 25 g dextrose (shift potassium intracellularly)
  • Sodium bicarbonate 50 mEq IV for the acidosis
  • Continuous cardiac monitoring

Subsequent Management:

  • Discontinue spironolactone and ibuprofen
  • Hold lisinopril temporarily
  • Sodium polystyrene sulfonate 30 g orally
  • Consider dialysis if refractory
  • Potassium-restricted diet

Clinical Pearl

The combination of ACE inhibitor, mineralocorticoid receptor antagonist, and NSAID in a patient with CKD and diabetes represents a "perfect storm" for hyperkalemia. Each medication alone may be tolerated, but together they can precipitate life-threatening hyperkalemia.


All cases for this lecture as Markdown